Back to search

Article

Pausing Methotrexate Prevents Impairment of Omicron BA.1 and BA.2 Neutralization after COVID-19 Booster Vaccination

2022-07-26

Abstract excerpt

Background: The level of neutralizing capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous MTX therapy is unclear.<br><br>Methods: In this observational cohort study, neutralizing serum activity against SARS-CoV-2 wildtype (Wu01) and variant of concern (VOC) Omicron BA.1 and BA.2 were assessed by pseudovirus neutralization assay before, 4 and 12 weeks after mR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8ae7ea67-3588-5c51-ba91-c89ac8b3f9f1
DOI
10.2139/ssrn.4173042
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pausing Methotrexate Prevents Impairment of Omicron BA.1 and BA.2 Neutralization after COVID-19 Booster VaccinationDOI 10.2139/ssrn.4173042
Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate TherapySemantic proximity
Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccinationSemantic proximity
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patientsSemantic proximity
Effects of the Second Dose of COVID-19 Vaccines in Patients with Autoimmune Rheumatic Diseases with Hybrid ImmunitySemantic proximity
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED StudySemantic proximity
Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying DrugsSemantic proximity
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseaseSemantic proximity
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort StudySemantic proximity
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273Semantic proximity
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort studySemantic proximity
Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity
COVID-19 prevention with alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomideSemantic proximity
Select a neighboring publication to make it the new centre.